Prochymal^® Phase 3 Clinical Trial for the Treatment of Newly Diagnosed Acute GvHD

Enrollment for this trial has been completed

The objective of this Phase 3 study is to evaluate the efficacy of Prochymal in combination with corticosteroids in subjects experiencing newly diagnosed Grade B-D acute GvHD. It is expected that the stem cells will distribute to areas of inflammation where they can repair the damaged tissue.

Trial Overview

Click Here for more information

If you have questions about this clinical program, please email us at GvHD@Osiris.com